News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Roche’s Avastin Rejected by U.K. Agency for Colorectal Cancer
November 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Roche Holding AG’s Avastin failed to win the backing of the U.K. National Institute for Health and Clinical Excellence for use in combination with chemotherapy against colorectal cancer that has spread.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Regulatory
Europe
Roche
MORE ON THIS TOPIC
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
October 16, 2025
·
1 min read
·
BioSpace Insights
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
October 15, 2025
·
2 min read
·
Tristan Manalac
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
·
1 min read
·
Heather McKenzie